SEC Form 4 · accession 0001140361-16-080230
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Sep 15, 2016
Accepted (ET)
Sep 19, 2016 · 6:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2016 | M | 42,577 | $17.33 | A | 421,161 | D | |
| Common StockF1,F2 | Sep 15, 2016 | S | 42,577 | $94.8484 | D | 378,584 | D | |
| Common StockF1 | Sep 16, 2016 | M | 53,125 | $38.59 | A | 431,709 | D | |
| Common StockF1,F3 | Sep 16, 2016 | S | 53,125 | $95.2478 | D | 378,584 | D | |
| Common StockF4 | Sep 16, 2016 | M | 41,666 | $17.54 | A | 420,250 | D | |
| Common StockF4,F5 | Sep 16, 2016 | S | 41,666 | $95.967 | D | 378,584 | D | |
| Common Stock | holding | — | — | — | 25,758 | I | Shares held by Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1,F6 | $17.33 | Sep 15, 2016 | M | 42,577 | D | Dec 7, 2007 | Jun 6, 2017 | Common Stock | 42,577 | 117,423 | D |
| Stock Option (right to buy Common Stock)F1,F6 | $38.59 | Sep 16, 2016 | M | 53,125 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 53,125 | 371,875 | D |
| Stock Option (right to buy Common Stock)F4,F6 | $17.54 | Sep 16, 2016 | M | 41,666 | D | May 20, 2007 | Nov 19, 2016 | Common Stock | 41,666 | 83,336 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $94.02 to $96.72. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The price in column 4 is the weighted average price. The price actually received ranged from $94.02 to $97.20. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the sale of these shares pursuant to a marital separation agreement between Mr. Bienaime and his former spouse.
- F5The price in column 4 is the weighted average price. The price actually received ranged from $94.365 to $97.21. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6Reflects the number of stock options outstanding after the transaction from this specific stock option grant.